Saftey and Efficacy of alternate day regimen of Oral Dutasteride in male patients with Androgenic Alopecia
Phase 3
- Conditions
- Health Condition 1: L649- Androgenic alopecia, unspecified
- Registration Number
- CTRI/2024/06/068777
- Lead Sponsor
- Dr Neil Patel
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Clinically diagnosed patients of androgenic alopecia not on any treatment in past 3 months
2.Patients willing to follow instruction and give informed consent
Exclusion Criteria
1.Previous allergic reactions to finasteride like compounds
2.Prior surgical correction of scalp hair loss
3.Patients with any other inflammatory/scarring lesion on scalp
4.Patients with chronic systemic illness (Tuberculosis, HIV)
5.Patients on drugs with significant interaction with dutasteride (CYP3A4 inducers/inhibitors)
6.Patients with cancer or first degree relative with prostate cancer before the age of 50
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method